The landscape of diabetes management is rapidly shifting, with the emergence of dual GIP and GLP-1 receptor agonists. Both Tirzepatide and Retatru tide represent key advancements; The Tirzepatide already https://nad-1539886.themartinblog.com/596378/tirzepatid-retatrutide-a-new-weight-management-combination